In the final analysis of a phase 1 trial evaluating a lymph node-targeting mutant KRAS peptide vaccine combined with CpG in the adjuvant setting for patients with KRAS mutant pancreatic or colorectal cancer, median relapse-free survival and overall survival were not reached for patients with robust antigen-specific T cell responses, and these responses were durable with evidence of antigen spreading. Here, KRAS is linked to colorectal cancer.